Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2026)

Cogent Biosciences (COGT) has reported Accumulated Expenses for 10 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 69.18% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 69.18% YoY), while the FY2025 annual figure was $15.7 million, down 62.64% from the prior year.
• Accumulated Expenses fell to $6.2 million in Q1 2026 per COGT's latest filing, from $15.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $42.1 million in Q4 2024 and bottomed at $1.5 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $10.5 million across 5 years, with a median of $7.7 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 1000.48% — and 2024, when it sank 84.81%.
• Cogent Biosciences' Accumulated Expenses stood at $17.9 million in 2022, then slumped by 44.79% to $9.9 million in 2023, then jumped by 326.7% to $42.1 million in 2024, then tumbled by 62.64% to $15.7 million in 2025, then sank by 60.58% to $6.2 million in 2026.
• Business Quant data shows COGT's Accumulated Expenses at $6.2 million in Q1 2026, $15.7 million in Q4 2025, and $10.5 million in Q3 2025.